Overview

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated interferon alpha and NAs.
Phase:
Phase 4
Details
Lead Sponsor:
Third Affiliated Hospital, Sun Yat-Sen University
Collaborators:
First People's Hospital of Foshan
First People's Hospital, Shunde China
Huazhong University of Science and Technology
Huizhou Municipal Central Hospital
Nanchang University
Peking University
Shenzhen Third People's Hospital
Tang-Du Hospital
The First Affiliated Hospital of Kunming Medical College
Yuebei People's Hospital
Treatments:
Peginterferon alfa-2a
Peginterferon alfa-2b